No Data
No Data
Amoy Diagnostics: Half-year report for the year 2024.
Amoy Diagnostics: Summary of Half-Year Report in 2024.
Amoy Diagnostics (300685.SZ): net income of 1.44 billion yuan in the first half of the year, an increase of 13.49% year-on-year.
Amoy Diagnostics (300685.SZ) released its H1 2024 report, with revenue of 0.543 billion yuan, an increase of 18.38% YoY, net income attributable to shareholders of the listed company of 0.144 billion yuan, an increase of 13.49% YoY, net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of 0.132 billion yuan, an increase of 20.72% YoY, and basic earnings per share of 0.36 yuan.
Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Business Is Trailing The Market But Its Shares Aren't
Express News | Amoy Diagnostics Says It Signs Cooperation Agreement With Les Laboratoires Servier on Products for Glioma Treatment
Amoy Diagnostics (300685.SZ) has reached a collaborative diagnostic partnership with Sysmex.
On June 26th, Gelunhui reported that Amoy Diagnostics (300685.SZ) recently signed a companion diagnostic cooperation agreement (hereinafter referred to as "the agreement") with LES LABORATOIRES SERVIER (hereinafter referred to as "Servier"). The company's independently developed second-generation sequencing (NGS) platform's companion diagnostic product is used to detect isocitrate dehydrogenase (IDH) 1 and 2 gene mutations. These companion diagnostic products will be used for Servier's investigational new drug, vorasidenib, which is a mutant isocitrate dehydrogenase 1 and 2 (IDH1 and I)
No Data